PMID- 38459988
OWN - NLM
STAT- Publisher
LR  - 20240309
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2024 Mar 9
TI  - Protective effect of alpha‑lipoic acid against in utero cytarabine 
      exposure-induced hepatotoxicity in rat female neonates.
LID - 10.1007/s00210-024-03036-4 [doi]
AB  - Cytarabine, an anti-metabolite drug, remains the mainstay of treatment for 
      hematological malignancies. It causes various toxic effects including 
      teratogenicity. Alpha lipoic acid (ALA) is a natural antioxidant reported to 
      offer protection against hepatotoxicity induced by various pathological 
      conditions, drugs, or chemicals. We investigated the protective effect of ALA 
      against prenatal cytarabine exposure-induced hepatotoxicity in rat female 
      neonates. A total of 30 dams were randomly assigned to five groups and received 
      normal saline, ALA 200 mg/kg, cytarabine 12.5 mg/kg, cytarabine 25 mg/kg, and 
      cytarabine 25 mg/kg + ALA 200 mg/kg, respectively, from gestational day (GD)8 to 
      GD21. Cytarabine and ALA were administered via intraperitoneal and oral (gavage) 
      routes, respectively. On postnatal day (PND)1, all the live female neonates 
      (pups) were collected and weighed. The blood and liver from pups were carefully 
      collected and used for histopathological, and biochemical evaluations. A 
      significant and dose-dependent decrease in maternal food intake and weight gain 
      was observed in the pregnant rats (dams) of the cytarabine groups as compared to 
      the dams of the control group. The pups exposed to cytarabine showed a 
      significant and dose-dependent (a) decrease in body weight, liver weight, 
      hepatosomatic index, catalase, superoxide dismutase, glutathione, glutathione 
      peroxidase, serum albumin levels and (b) increase in malondialdehyde, alanine 
      aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, 
      AST/ALT ratio, and histopathological anomalies. Maternal co-administration of ALA 
      ameliorated these biochemical changes and histopathological abnormalities by 
      combating oxidative stress. Future studies are warranted to explore the molecular 
      mechanisms involved in the ALA's protective effects against prenatal 
      cytarabine-induced hepatotoxicity.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Namoju, Ramanachary
AU  - Namoju R
AD  - Department of Pharmacology, GITAM School of Pharmacy, GITAM Deemed to be 
      University, Visakhapatnam, Andhra Pradesh, 530045, India. 1268116413@gitam.in.
AD  - Department of Pharmacology, Bhaskar Pharmacy College, Jawaharlal Nehru Technical 
      University, Hyderabad, Telangana, 500075, India. 1268116413@gitam.in.
FAU - Chilaka, Kavitha N
AU  - Chilaka KN
AD  - Department of Pharmacology, GITAM School of Pharmacy, GITAM Deemed to be 
      University, Visakhapatnam, Andhra Pradesh, 530045, India.
LA  - eng
PT  - Journal Article
DEP - 20240309
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
SB  - IM
OTO - NOTNLM
OT  - Alpha lipoic acid
OT  - Cytarabine
OT  - Hepatotoxicity
OT  - Neonatal
OT  - Oxidative stress
OT  - Prenatal
EDAT- 2024/03/09 20:43
MHDA- 2024/03/09 20:43
CRDT- 2024/03/09 11:04
PHST- 2023/11/05 00:00 [received]
PHST- 2024/03/01 00:00 [accepted]
PHST- 2024/03/09 20:43 [medline]
PHST- 2024/03/09 20:43 [pubmed]
PHST- 2024/03/09 11:04 [entrez]
AID - 10.1007/s00210-024-03036-4 [pii]
AID - 10.1007/s00210-024-03036-4 [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2024 Mar 9. doi: 10.1007/s00210-024-03036-4.